1. Home
  2. WHF vs RANI Comparison

WHF vs RANI Comparison

Compare WHF & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$6.75

Market Cap

144.8M

Sector

Finance

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$0.95

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHF
RANI
Founded
2011
2012
Country
United States
United States
Employees
3
N/A
Industry
Finance Companies
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
144.8M
126.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WHF
RANI
Price
$6.75
$0.95
Analyst Decision
Sell
Strong Buy
Analyst Count
2
4
Target Price
$7.75
$7.50
AVG Volume (30 Days)
97.8K
1.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
13.67%
N/A
EPS Growth
N/A
57.14
EPS
N/A
N/A
Revenue
N/A
$1,633,000.00
Revenue This Year
N/A
$274.77
Revenue Next Year
N/A
$79.44
P/E Ratio
$15.35
N/A
Revenue Growth
N/A
58.85
52 Week Low
$6.07
$0.39
52 Week High
$9.66
$3.87

Technical Indicators

Market Signals
Indicator
WHF
RANI
Relative Strength Index (RSI) 35.34 47.57
Support Level $6.44 $0.86
Resistance Level $7.24 $1.10
Average True Range (ATR) 0.22 0.09
MACD -0.07 -0.01
Stochastic Oscillator 29.46 28.23

Price Performance

Historical Comparison
WHF
RANI

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: